Named Bioactive Compounds · Compound
Sanguinarine (Benzophenanthridine Alkaloid)
Moderate Evidencealkaloid
Hermetica Superfood Encyclopedia
Sanguinarine is a benzophenanthridine alkaloid derived from bloodroot (Sanguinaria canadensis) that demonstrates anticancer properties through apoptosis induction and cell cycle arrest. This quaternary ammonium alkaloid primarily targets DNA intercalation and topoisomerase inhibition pathways.
Sanguinarine is a benzophenanthridine alkaloid extracted from the rhizomes of Sanguinaria canadensis (bloodroot), a plant native to North America. It belongs to the isoquinoline alkaloid family and is typically isolated from plant tissue through various extraction protocols.
Current evidence is limited entirely to in vitro and animal studies, with no human clinical trials published. Key studies include prostate cancer research (PMID: 15299076) showing dose-dependent growth inhibition at 0.1-2 μmol/L, and multiple lung cancer cell line investigations using MTT assays, wound healing assays, and transwell assays. No Phase I, II, or III human trials exist.
No clinically studied dosage ranges are available as human clinical trials have not been conducted. Laboratory studies used concentrations of 0.1-2 μmol/L in cell cultures, but these cannot be translated to human dosing. Sanguinarine is not considered safe for clinical use due to toxicity concerns. Consult a healthcare provider before starting any new supplement.
Sanguinarine is not a nutrient but a toxic quaternary benzophenanthridine alkaloid (molecular formula: C₂₀H₁₄NO₄⁺, MW: 332.33 g/mol). It is a bioactive secondary metabolite, not consumed for nutritional value. Key biochemical characteristics: • Found naturally in plants of the Papaveraceae family, particularly Sanguinaria canadensis (bloodroot), Chelidonium majus (greater celandine), Macleaya cordata (plume poppy), and Argemone mexicana (Mexican prickly poppy). Concentrations in bloodroot rhizome range from approximately 1–6% dry weight. • Primary bioactive form: quaternary ammonium cation; exists in charged (iminium) and pseudobase (alkanolamine) forms depending on pH — the charged form predominates at physiological pH and intercalates DNA. • Bioavailability: Oral bioavailability is considered low-to-moderate due to significant first-pass hepatic metabolism; sanguinarine is rapidly metabolized to dihydrosanguinarine (reduced form) in the liver and GI tract. Protein binding is high (binds strongly to serum albumin and tissue proteins). It accumulates preferentially in liver and GI tissues. • No macronutrient value (zero calories, protein, fat, carbohydrate, or fiber). • No vitamin or mineral content. • Key related co-occurring alkaloids in source plants: chelerythrine (structurally analogous benzophenanthridine), berberine, protopine, allocryptopine, and chelidonine — these may contribute to synergistic or additive bioactivity. • Typical research doses in cell culture studies: 0.5–10 µM; animal study doses: 1–10 mg/kg body weight. Human exposure is primarily through dental products (toothpastes/mouthwashes historically contained ~0.03% sanguinarine extract, now largely discontinued due to association with oral leukoplakia). • Safety note: Sanguinarine is cytotoxic and classified as a toxin at higher doses. It inhibits Na⁺/K⁺-ATPase, disrupts mitochondrial function, and has caused epidemic dropsy when consumed via Argemone oil-contaminated mustard oil. LD₅₀ in rats (intravenous): ~28 mg/kg. Not approved as a dietary supplement or food additive by FDA/EFSA.
Sanguinarine intercalates with DNA double helix structure, disrupting normal replication and transcription processes. The compound inhibits topoisomerase I and II enzymes, leading to DNA strand breaks and subsequent activation of p53-mediated apoptotic pathways. Additionally, sanguinarine modulates NF-κB signaling cascades and induces G1/S cell cycle arrest through cyclin-dependent kinase inhibition.
Current evidence for sanguinarine is limited to preclinical laboratory studies using cancer cell lines. In vitro research shows IC50 values ranging from 2-8 μM against lung cancer cells (H1299, H1975, H460, A549), with colony formation reduced by 60-80% at these concentrations. Animal studies demonstrate tumor growth inhibition of 40-55% in xenograft models, but no human clinical trials have been conducted. The evidence remains preliminary and requires clinical validation for therapeutic applications.
Sanguinarine exhibits significant toxicity concerns due to its DNA-intercalating properties, with potential for cellular damage in healthy tissues. The compound may interact with chemotherapy drugs and anticoagulants through cytochrome P450 enzyme modulation. Topical applications can cause severe skin irritation and tissue necrosis at concentrations above 0.1%. Pregnancy and breastfeeding safety is unknown, and use should be avoided due to potential teratogenic effects from DNA intercalation mechanisms.
